A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 30 May 2025
At a glance
- Drugs BL M11D1 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors SystImmune
Most Recent Events
- 29 Apr 2025 Status changed from not yet recruiting to recruiting.
- 26 Nov 2024 According to a SystImmune media release, the company will present Initial results from First-in-Human Phase 1 Study at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted Monday, December 9th, 2024, 6:00 PM-8:00 PM PST in San Diego, CA.
- 15 Oct 2024 New trial record